1. Home
  2. EPSN vs MGNX Comparison

EPSN vs MGNX Comparison

Compare EPSN & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Epsilon Energy Ltd.

EPSN

Epsilon Energy Ltd.

HOLD

Current Price

$5.66

Market Cap

187.2M

Sector

Energy

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$4.30

Market Cap

220.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EPSN
MGNX
Founded
2005
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
187.2M
220.6M
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
EPSN
MGNX
Price
$5.66
$4.30
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$5.00
AVG Volume (30 Days)
177.0K
1.4M
Earning Date
05-13-2026
05-08-2026
Dividend Yield
4.01%
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
N/A
$149,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.19
P/E Ratio
$281.50
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.20
$1.30
52 Week High
$6.65
$5.08

Technical Indicators

Market Signals
Indicator
EPSN
MGNX
Relative Strength Index (RSI) 55.68 48.12
Support Level $5.57 $1.49
Resistance Level $5.96 $4.55
Average True Range (ATR) 0.21 0.33
MACD 0.05 -0.05
Stochastic Oscillator 75.97 27.49

Price Performance

Historical Comparison
EPSN
MGNX

About EPSN Epsilon Energy Ltd.

Epsilon Energy Ltd is a North American on-shore focused independent natural gas and oil company engaged in the acquisition, development, gathering and production of natural gas and oil reserves. Its properties include Appalachian Basin-Pennsylvania, Permian Basin-Texas and New Mexico, Anadarko Basin-Oklahoma, Powder River Basin-Wyoming, Western Canadian Sedimentary Basin-Alberta, Canada. Its segments include The Upstream segment activities include acquisition, development and production of natural gas and oil reserves on properties within the United States and Canada; and The Gas Gathering segment partners with two other companies to operate a natural gas gathering system. The Upstream segment derives the majority of the revenue.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: